The trade war between the United States and China has lasted for more than one year — and a resolution is nowhere in sight.World Economyread more
The Fed is expected to cut rates Wednesday, but it is unlikely to tell markets what they want to hear on future rate cuts.Market Insiderread more
Pelosi said Trump should not have tried to address China's trade practices in a way that opened Americans up to financial pain.Politicsread more
Investors await the Fed's latest decision on monetary policy, set to be released on Wednesday stateside. The U.S. central bank is widely expected to cut rates by 25 basis...Asia Marketsread more
TransferWise posted an annual net profit of £10.3 million on revenues of £179 million.Technologyread more
Live the high life with a night's stay at Highclere Castle, the iconic stately home made famous by Downton Abbey.Spendread more
Large banking institutions face the risk of failure if interest rates in Europe continue to stay negative, warns the global chief economist of the Economist Intelligence Unit.Banksread more
The fallout from two fatal crashes of Boeing 737 Max planes has ensnared the manufacturer's most-loyal customer: Southwest Airlines. The carrier has canceled thousands of...Airlinesread more
Brent crude oil jumped the most in history in the previous session after attacks on Saudi's oil industry disrupted the kingdom's production.Marketsread more
In the survey, conducted after the third in the Democratic Party's series of debate, the former vice president draws 31% compared to 25% for the Massachusetts senator. At 14%,...2020 Electionsread more
Stocks rose slightly on Tuesday, but gains were capped as the Federal Reserve kicked off a two-day monetary policy meeting.US Marketsread more
The Food and Drug Administration released a list Tuesday of medicines at most risk for price hiking of the Martin Shkreli variety: those that have lost patent protection but have no generic competition.
That list includes Daraprim, or pyrimethamine, the anti-parasitic drug whose price Shkreli hiked 5,000 percent as CEO of Turing Pharmaceuticals in 2015, vaulting him to international infamy that's even affecting jury selection in his just-started fraud trial.
But the FDA's new list — designed to spur generic competition to bring down prices or deter gougers in the first place — may hold a bigger risk for another company, according to Wells Fargo analyst David Maris: Valeant.
"While the list encompasses a large number of branded products from many manufacturers, our review shows no company in our coverage universe is more exposed to this new FDA effort than Valeant," Maris wrote in a research note Tuesday.
He estimates, citing data from industry researcher IMS Health, that products included on the FDA's list generated $713 million in 2016 revenue for Valeant. That's out of a total $9.67 billion in sales last year.
"We note that some of these products are listed by Valeant as at risk of facing potential competition in the coming years," Maris wrote. "However, what is new is the FDA's focus on expediting competition on these products. We believe this is a risk factor for investors to be aware."
Those drugs include Lotemax, an eye product from Valeant-owned Bausch + Lomb that drew $218.6 million in sales last year, as well as Syprine and Cuprimine, medicines for Wilson's disease that were highlighted in a congressional hearing last year on Valeant's price hikes. Those medicines drew $147.4 million and $170.6 million in 2016 sales, respectively, according to Maris' note.
"If generics [companies] are not already working on these, they will now," Maris told CNBC in an email. "It is a shopping list. For the generic companies already working on these, the FDA news is great for them as it shows their filings, if early, will get priority."
Valeant didn't immediately respond to a request for comment. The company's new CEO, Joe Papa, has repeatedly said the troubled drugmaker is turning over a new leaf, moving on from its acquisition-fueled, price-hiking strategies that cast it in the same light as Shkreli's Turing.
Some industry watchers responded with skepticism that the FDA's list would be used to promote competition to bring down prices, rather than as a blueprint for which drugs are ripe for that kind of exploitation.
As for the so-called pharma bro, Shkreli is facing eight counts of securities fraud, conspiracy to commit securities fraud and conspiracy to commit wire fraud in a federal court case taking place in Brooklyn, New York.
Though the charges have nothing to do with his price hike on Daraprim, a number of potential jurors were dismissed because they associate Shkreli with those actions. One called him "the face of corporate greed."